R. D. Arbeit, D. Maki, F. P. Tally, E. Campanaro, and B. I. Eisenstein, Investigators D 98-01 and 99-01. The Safety and Efficacy of Daptomycin for the Treatment of Complicated Skin and Skin-Structure Infections, Clin Infect Dis, vol.38, issue.12, pp.1673-81, 2004.

, Antimicrobial resistance surveillance in Europe, 2013.

F. Santé-publique, Résistance aux anti-infectieux". *En ligne+. *Internet+. *cited, 2017.

F. C. Tenover, Implications of vancomycin-resistant Staphylococcus aureus, J Hosp Infect, vol.43, pp.3-7, 1999.

A. Uttley, R. C. George, J. Naidoo, N. Woodford, A. P. Johnson et al., High-level vancomycin-resistant enterococci causing hospital infections. Epidemiol Amp Infect, vol.103, pp.173-81, 1989.

K. Hiramatsu, H. Hanaki, T. Ino, K. Yabuta, T. Oguri et al., Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility, J Antimicrob Chemother, vol.40, issue.1, pp.135-141, 1997.

S. Chang, D. M. Sievert, J. C. Hageman, M. L. Boulton, F. C. Tenover et al., Infection with Vancomycin-Resistant Staphylococcus aureus Containing the vanA Resistance Gene, N Engl J Med, vol.3, issue.14, pp.1342-1349, 2003.

F. Ehlert and H. C. Neu, In vitro activity of LY146032 (daptomycin), a new peptolide, Eur J Clin Microbiol, vol.6, issue.1, pp.84-90, 1987.

J. H. Jorgensen, L. A. Maher, and J. S. Redding, In vitro activity of LY146032 (daptomycin) against selected aerobic bacteria, Eur J Clin Microbiol, vol.6, issue.1, pp.91-96, 1987.

K. Machka and I. Braveny, Comparative in vitro activity of LY146032 (daptomycin) against gram-positive cocci, Eur J Clin Microbiol, vol.6, issue.1, pp.96-99, 1987.

L. Jeu and H. B. Fung, Daptomycin: a cyclic lipopeptide antimicrobial agent, Clin Ther, vol.26, issue.11, pp.1728-1757, 2004.

M. A. Mchenney, T. J. Hosted, B. S. Dehoff, P. R. Rosteck, and R. H. Baltz, Molecular cloning and physical mapping of the daptomycin gene cluster from Streptomyces roseosporus, J Bacteriol, vol.180, issue.1, pp.143-151, 1998.

N. Woodford, Novel agents for the treatment of resistant Gram-positive infections, Expert Opin Investig Drugs, vol.12, issue.2, pp.117-154, 2003.

S. K. Straus and R. Hancock, Mode of action of the new antibiotic for Gram-positive pathogens daptomycin: Comparison with cationic antimicrobial peptides and lipopeptides, Biochim Biophys Acta BBA-Biomembr, vol.1758, issue.9, pp.1215-1238, 2006.

W. E. Alborn, N. E. Allen, and D. A. Preston, Daptomycin disrupts membrane potential in growing Staphylococcus aureus, Antimicrob Agents Chemother, vol.35, issue.11, pp.2282-2287, 1991.

J. A. Silverman, N. G. Perlmutter, and H. M. Shapiro, Correlation of Daptomycin Bactericidal Activity and Membrane Depolarization in Staphylococcus aureus, Antimicrob Agents Chemother, vol.47, issue.8, pp.2538-2582, 2003.

, Revue des antibiotiques utilisés pour le traitement d'une infection à Staphylococcus aureus résistant à la Methicilline chez le patient adulte hospitalisé, 2017.

W. R. Miller, A. S. Bayer, and C. A. Arias, Mechanism of Action and Resistance to Daptomycin in Staphylococcus aureus and Enterococci. Cold Spring Harb Perspect Med, vol.6, p.26997, 2016.

Y. Chen, T. Sun, Y. Sun, and H. W. Huang, Interaction of Daptomycin with Lipid Bilayers: A Lipid Extracting Effect. Biochemistry (Mosc), vol.53, pp.5384-92, 2014.

R. Hancock, Mechanisms of action of newer antibiotics for Gram-positive pathogens, Lancet Infect Dis, vol.5, issue.4, pp.209-227, 2005.

F. P. Tally and M. F. Debruin, Development of daptomycin for Gram-positive infections, J Antimicrob Chemother, vol.46, issue.4, pp.523-529, 2000.

. Hanberger-h-akan, L. E. Nilsson, R. Maller, and B. Isaksson, Pharmacodynamics of daptomycin and vancomycin on Enterococcus faecalis and Staphylococcus aureus demonstrated by studies of initial killing and postantibiotic effect and influence of Ca2+ and albumin on these drugs, Antimicrob Agents Chemother, vol.35, issue.9, pp.1710-1716, 1991.

F. P. Tally, M. Zeckel, M. M. Wasilewski, C. Carini, C. L. Berman et al., Daptomycin: a novel agent for Gram-positive infections, Expert Opin Investig Drugs, vol.8, issue.8, pp.1223-1261, 1999.

K. C. Lamp, M. J. Rybak, E. M. Bailey, and G. W. Kaatz, In vitro pharmacodynamic effects of concentration, pH, and growth phase on serum bactericidal activities of daptomycin and vancomycin, Antimicrob Agents Chemother, vol.36, issue.12, pp.2709-2723, 1992.

K. Smith, A. Perez, G. Ramage, C. G. Gemmell, and S. Lang, Comparison of biofilm-associated cell survival following in vitro exposure of meticillin-resistant Staphylococcus aureus biofilms to the antibiotics clindamycin, daptomycin, linezolid, tigecycline and vancomycin, Int J Antimicrob Agents, vol.33, issue.4, pp.374-382, 2009.

I. Raad, H. Hanna, Y. Jiang, T. Dvorak, R. Reitzel et al., Comparative Activities of Daptomycin, Linezolid, and Tigecycline against Catheter-Related Methicillin-Resistant Staphylococcus Bacteremic Isolates Embedded in Biofilm, Antimicrob Agents Chemother, vol.51, issue.5, pp.1656-60, 2007.

M. K. Luther, M. Arvanitis, E. Mylonakis, and K. L. Laplante, Activity of Daptomycin or Linezolid in Combination with Rifampin or Gentamicin against Biofilm-Forming Enterococcus faecalis or E. faecium in an In Vitro Pharmacodynamic Model Using Simulated Endocardial Vegetations and an In Vivo Survival Assay Using Galleria mellonella Larvae, Antimicrob Agents Chemother, vol.58, issue.8, pp.4612-4632, 2014.

C. F. Carpenter and H. F. Chambers, Daptomycin: Another novel agent for treating infections due to drug-resistant gram-positive pathogens, Clin Infect Dis, vol.38, issue.7, pp.994-1000, 2004.

F. B. Oleson, C. L. Berman, J. B. Kirkpatrick, K. S. Regan, J. Lai et al., Once-daily dosing in dogs optimizes daptomycin safety, Antimicrob Agents Chemother, vol.44, issue.11, pp.2948-2953, 2000.

G. M. Eliopoulos, C. Thauvin, B. Gerson, and R. C. Moellering, In vitro activity and mechanism of action of A21978C1, a novel cyclic lipopeptide antibiotic, Antimicrob Agents Chemother, vol.27, issue.3, pp.357-362, 1985.

R. N. Jones and A. L. Barry, Antimicrobial activity and spectrum of LY146032, a lipopeptide antibiotic, including susceptibility testing recommendations, Antimicrob Agents Chemother, vol.31, issue.4, pp.625-629, 1987.

R. L. Hodinka, K. Jack-wait, N. Wannamaker, T. P. Walden, and P. H. Gilligan, Comparative in vitro activity of IY146032 (daptomycin), a new lipopeptide antimicrobial, Eur J Clin Microbiol Infect Dis, vol.6, issue.1, pp.100-103, 1987.

R. J. Fass and V. L. Helsel, In vitro activity of LY146032 against staphylococci, streptococci, and enterococci, Antimicrob Agents Chemother, vol.30, issue.5, pp.781-784, 1986.

R. M. Humphries, S. Pollett, and G. Sakoulas, A Current Perspective on Daptomycin for the Clinical Microbiologist, Clin Microbiol Rev, vol.26, issue.4, pp.759-80, 2013.

Y. Huang, C. Liao, L. Teng, and P. Hsueh, Daptomycin Susceptibility of Unusual GramPositive Bacteria: Comparison of Results Obtained by the Etest and the Broth Microdilution Method, Antimicrob Agents Chemother, vol.51, issue.4, pp.1570-1572, 2007.

E. Goldstein, D. M. Citron, C. V. Merriam, Y. A. Warren, K. L. Tyrrell et al., Quinupristin-Dalfopristin, Linezolid, and Five Other Antimicrobials against 307 Gram-Positive Anaerobic and 31 Corynebacterium Clinical Isolates, Vitro Activities of Daptomycin, Vancomycin, vol.47, pp.337-378, 2003.
DOI : 10.1128/aac.47.4.1486.2003

URL : https://aac.asm.org/content/47/4/1486.full.pdf

D. R. Snydman, N. V. Jacobus, L. A. Mcdermott, J. R. Lonks, and J. M. Boyce, Comparative In Vitro Activities of Daptomycin and Vancomycin against Resistant Gram-Positive Pathogens, Antimicrob Agents Chemother, vol.44, issue.12, pp.3447-50, 2000.

P. J. Petersen, P. A. Bradford, W. J. Weiss, T. M. Murphy, P. E. Sum et al., Daptomycin, and Comparative Antimicrobial Agents against Glycopeptide-Intermediate Staphylococcus aureus and Other Resistant Gram-Positive Pathogens, Vitro and In Vivo Activities of Tigecycline (GAR-936), vol.46, pp.2595-601, 2002.
DOI : 10.1128/aac.46.8.2595-2601.2002

URL : https://aac.asm.org/content/46/8/2595.full.pdf

K. C. Molina and V. Huang, Resistance to Non-glycopeptide Agents in Serious Staphylococcus aureus Infections, Curr Infect Dis Rep, vol.18, issue.12, p.47, 2016.

C. L. Moore, P. Osaki-kiyan, N. Z. Haque, M. B. Perri, S. Donabedian et al., Daptomycin Versus Vancomycin for Bloodstream Infections Due to Methicillin-Resistant Staphylococcus aureus With a High Vancomycin Minimum Inhibitory Concentration: A Case-Control Study, Clin Infect Dis, vol.54, issue.1, pp.51-59, 2012.

P. A. Moise, D. L. Culshaw, A. Wong-beringer, J. Bensman, K. C. Lamp et al., Comparative Effectiveness of Vancomycin Versus Daptomycin for MRSA Bacteremia With Vancomycin MIC >1 mg/L: A Multicenter Evaluation, Clin Ther, vol.38, issue.1, pp.16-30, 2016.

K. P. Murray, J. J. Zhao, S. L. Davis, R. Kullar, K. S. Kaye et al., Early Use of Daptomycin Versus Vancomycin for Methicillin-Resistant Staphylococcus aureus Bacteremia With Vancomycin Minimum Inhibitory Concentration >1 mg/L: A Matched Cohort Study, Clin Infect Dis, vol.56, issue.11, pp.1562-1571, 2013.

H. S. Sader, D. J. Farrell, R. K. Flamm, and R. N. Jones, Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: Summary of 8 years of a Worldwide Surveillance Programme, Int J Antimicrob Agents, vol.43, issue.5, pp.465-474, 2005.

A. Mangili, I. Bica, D. R. Snydman, and D. H. Hamer, Daptomycin-resistant, methicillin-resistant Staphylococcus aureus bacteremia, Clin Infect Dis, vol.40, issue.7, pp.1058-1060, 2005.

M. K. Hayden, K. Rezai, R. A. Hayes, K. Lolans, J. P. Quinn et al., Development of Daptomycin Resistance In Vivo in Methicillin-Resistant Staphylococcus aureus, J Clin Microbiol, vol.43, issue.10, pp.5285-5292, 2005.

K. Sabol, J. E. Patterson, J. S. Lewis, A. Owens, J. Cadena et al., Emergence of Daptomycin Resistance in Enterococcus faecium during Daptomycin Therapy, Antimicrob Agents Chemother, vol.49, issue.4, pp.1664-1669, 2005.

F. M. Marty, W. W. Yeh, C. B. Wennersten, L. Venkataraman, E. Albano et al., Emergence of a Clinical Daptomycin-Resistant Staphylococcus aureus Isolate during Treatment of Methicillin-Resistant Staphylococcus aureus Bacteremia and Osteomyelitis, J Clin Microbiol, vol.44, issue.2, pp.595-602, 2006.

F. Jr, V. G. Boucher, H. W. Corey, G. R. Abrutyn, E. Karchmer et al., Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus, N Engl J Med, vol.355, issue.7, pp.653-665, 2006.

G. W. Kaatz, T. S. Lundstrom, and S. M. Seo, Mechanisms of daptomycin resistance in Staphylococcus aureus, Int J Antimicrob Agents, vol.28, issue.4, pp.280-287, 2006.

T. Jones, M. R. Yeaman, G. Sakoulas, S. Yang, R. A. Proctor et al., Failures in Clinical Treatment of Staphylococcus aureus Infection with Daptomycin Are Associated with Alterations in Surface Charge, Membrane Phospholipid Asymmetry, and Drug Binding, Antimicrob Agents Chemother, vol.52, issue.1, pp.269-78, 2008.

N. N. Mishra, A. S. Bayer, T. T. Tran, Y. Shamoo, E. Mileykovskaya et al., Daptomycin Resistance in Enterococci Is Associated with Distinct Alterations of Cell Membrane Phospholipid Content, PLoS ONE, vol.7, issue.8, p.43958, 2012.

N. Bionda, J. Pitteloud, and P. Cudic, Cyclic lipodepsipeptides: a new class of antibacterial agents in the battle against resistant bacteria, Future Med Chem, vol.5, issue.11, pp.1311-1341, 2013.

P. Staubitz, H. Neumann, T. Schneider, I. Wiedemann, and A. Peschel, MprF-mediated biosynthesis of lysylphosphatidylglycerol, an important determinant in staphylococcal defensin resistance, FEMS Microbiol Lett, vol.231, issue.1, pp.67-71, 2004.

C. M. Ernst, P. Staubitz, N. N. Mishra, S. Yang, G. Hornig et al., The Bacterial Defensin Resistance Protein MprF Consists of Separable Domains for Lipid Lysinylation and Antimicrobial Peptide Repulsion, PLoS Pathog, vol.5, issue.11, p.1000660, 2009.

L. Friedman, J. D. Alder, and J. A. Silverman, Genetic Changes That Correlate with Reduced Susceptibility to Daptomycin in Staphylococcus aureus, Antimicrob Agents Chemother, vol.50, issue.6, pp.2137-2182, 2006.

N. N. Mishra, S. Yang, A. Sawa, A. Rubio, C. C. Nast et al., Analysis of Cell Membrane Characteristics of In Vitro-Selected Daptomycin-Resistant Strains of Methicillin-Resistant Staphylococcus aureus, Antimicrob Agents Chemother, vol.53, issue.6, pp.2312-2320, 2009.

S. Yang, Y. Q. Xiong, P. M. Dunman, J. Schrenzel, P. Francois et al., Regulation of mprF in Daptomycin-Nonsusceptible Staphylococcus aureus Strains, Antimicrob Agents Chemother, vol.53, issue.6, pp.2636-2643, 2009.

A. Y. Peleg, S. Miyakis, D. V. Ward, A. M. Earl, A. Rubio et al., Whole Genome Characterization of the Mechanisms of Daptomycin Resistance in Clinical and Laboratory Derived Isolates of Staphylococcus aureus, PLoS ONE, vol.7, issue.1, p.28316, 2012.

C. A. Arias, D. Panesso, D. M. Mcgrath, X. Qin, M. F. Mojica et al., Genetic basis for in vivo daptomycin resistance in enterococci, N Engl J Med, vol.365, issue.10, pp.892-900, 2011.

J. A. Silverman, L. I. Mortin, A. Vanpraagh, T. Li, and J. Alder, Inhibition of Daptomycin by Pulmonary Surfactant: In Vitro Modeling and Clinical Impact, J Infect Dis, vol.191, issue.12, pp.2149-52, 2005.

P. E. Pertel, P. Bernardo, C. Fogarty, P. Matthews, R. Northland et al., Effects of Prior Effective Therapy on the Efficacy of Daptomycin and Ceftriaxone for the Treatment of Community-Acquired Pneumonia, Clin Infect Dis, vol.46, issue.8, pp.1142-51, 2008.

J. R. Woodworth, E. H. Nyhart, G. L. Brier, J. D. Wolny, and H. R. Black, Single-dose pharmacokinetics and antibacterial activity of daptomycin, a new lipopeptide antibiotic, in healthy volunteers, Antimicrob Agents Chemother, vol.36, issue.2, pp.318-325, 1992.

B. H. Dvorchik, D. Brazier, M. F. Debruin, and R. D. Arbeit, Daptomycin Pharmacokinetics and Safety following Administration of Escalating Doses Once Daily to Healthy Subjects, Antimicrob Agents Chemother, vol.47, issue.4, pp.1318-1341, 2003.

D. E. Katz, K. C. Lindfield, J. N. Steenbergen, D. P. Benziger, K. J. Blackerby et al., A pilot study of high-dose short duration daptomycin for the treatment of patients with complicated skin and skin structure infections caused by gram-positive bacteria: Highdose short duration daptomycin, Int J Clin Pract, vol.62, issue.9, pp.1455-64, 2008.

. Merck-&-co and . Inc, Cubicin ® (daptomycin for injection) for intra-venous use full prescribing information, 2015.

, ANSM : Agence nationale de sécurité du médicament et des produits de santé, 2017.

C. Research, Postmarket Drug Safety Information for Patients and ProvidersFDA Drug Safety Communication: Eosinophilic pneumonia associated with the use of Cubicin (daptomycin), 2017.

D. Hayes, M. I. Anstead, and R. J. Kuhn, Eosinophilic pneumonia induced by daptomycin, J Infect, vol.54, issue.4, pp.211-214, 2007.

J. Hirai, M. Hagihara, S. Haranaga, T. Kinjo, H. Hashioka et al., Eosinophilic pneumonia caused by daptomycin: Six cases from two institutions and a review of the literature, J Infect Chemother, vol.23, issue.4, pp.245-254, 2017.

E. Cobb, R. C. Kimbrough, K. M. Nugent, and M. P. Phy, Organizing Pneumonia and Pulmonary Eosinophilic Infiltration Associated with Daptomycin, Ann Pharmacother, vol.41, issue.4, pp.696-701, 2007.

Y. Lal and A. P. Assimacopoulos, Two Cases of Daptomycin-Induced Eosinophilic Pneumonia and Chronic Pneumonitis, Clin Infect Dis, vol.50, issue.5, pp.737-777, 2010.

P. Uppal, K. L. Laplante, M. M. Gaitanis, M. D. Jankowich, and K. E. Ward, Daptomycin-induced eosinophilic pneumonia-a systematic review, Antimicrob Resist Infect Control, vol.5, 2016.

R. Produit, , 2017.

, Drugs@FDA: FDA Approved Drug Products, 2017.

C. Liu, A. Bayer, S. E. Cosgrove, R. S. Daum, S. K. Fridkin et al., Clinical Practice Guidelines by the Infectious Diseases Society of America for the Treatment of Methicillin-Resistant Staphylococcus aureus Infections in Adults and Children, Clin Infect Dis, vol.52, issue.3, pp.18-55, 2011.

G. Habib, P. Lancellotti, M. J. Antunes, M. G. Bongiorni, J. Casalta et al., ESC Guidelines for the management of infective endocarditis: The Task Force for the Management of Infective Endocarditis of the European Society of Cardiology (ESC)Endorsed by: European Association for Cardio-Thoracic Surgery (EACTS), the European Association of Nuclear Medicine (EANM), Eur Heart J, vol.36, issue.44, pp.3075-128, 2015.

A. ,

. Antibioguide, , 2016.

, Surveillance de la consommation des antibiotiques-Réseau ATB-Raisin / 2016 / Maladies infectieuses / Rapports et synthèses / Publications et outils / Accueil, 2017.

, Les antibiotiques considérés comme "critiques" : premières réflexions sur leur caractérisation-Point d'information-ANSM : Agence nationale de sécurité du médicament et des produits de santé, 2017.

E. Durante-mangoni, R. Andini, A. Parrella, I. Mattucci, G. Cavezza et al., Safety of treatment with high-dose daptomycin in 102 patients with infective endocarditis, Int J Antimicrob Agents, vol.48, issue.1, pp.61-69, 2016.

M. Rybak, B. Lomaestro, J. C. Rotschafer, R. Moellering, W. Craig et al., Therapeutic monitoring of vancomycin in adult patients: A consensus review of the American Society of Health-System Pharmacists, the Infectious Diseases Society of America, and the Society of Infectious Diseases Pharmacists, Am J Health Syst Pharm, vol.66, issue.1, pp.82-98, 2009.

R. Dantes, National Burden of Invasive Methicillin-Resistant Staphylococcus aureus Infections, United States, JAMA Intern Med, 2011.

,

G. Ic, . Van-den-broek, K. Pj, H. Ya, . Van-der-meer et al., Optimizing antimicrobial therapy. A method for antimicrobial drug me evaluation, J Antimicrob Chemother, vol.30, issue.5, pp.724-727, 1992.

F. Marc, C. Esquirol, E. Papy, P. Longuet, L. Armand-lefevre et al., A retrospective study of daptomycin use in a Paris teaching-hospital. Médecine Mal Infect, vol.44, pp.25-31, 2014.

A. Maurier and F. M. , Posters du 80e congrès-Daptomycine : analyse prospective sur une année au CHU d'Angers

. Apho, , 2017.

R. A. Seaton, A. Gonzalez-ruiz, K. O. Cleveland, K. A. Couch, R. Pathan et al., Real-world daptomycin use across wide geographical regions: results from a pooled analysis of CORE and EU-CORE, Ann Clin Microbiol Antimicrob, 2016.

H. S. Sader, D. J. Farrell, R. K. Flamm, and R. N. Jones, Daptomycin activity tested against 164457 bacterial isolates from hospitalised patients: Summary of 8 years of a Worldwide Surveillance Programme, Int J Antimicrob Agents, vol.43, issue.5, pp.465-474, 2005.

O. Gasch, M. Camoez, M. A. Domínguez, B. Padilla, V. Pintado et al., Emergence of resistance to daptomycin in a cohort of patients with methicillin-resistant Staphylococcus aureus persistent bacteraemia treated with daptomycin, J Antimicrob Chemother, vol.69, issue.2, pp.568-71, 2014.

A. Chow, N. N. Win, P. Y. Ng, W. Lee, and M. K. Win, Vancomycin-resistant enterococci with reduced daptomycin susceptibility in Singapore: prevalence and associated factors, Epidemiol Infect, vol.144, issue.12, pp.2540-2545, 2016.

T. Kelesidis, A. Chow, R. Humphries, D. Z. Uslan, and D. Pegues, Case-Control Study Comparing De Novo and Daptomycin-Exposed Daptomycin-Nonsusceptible Enterococcus Infections, Antimicrob Agents Chemother, vol.56, issue.4, pp.2150-2152, 2012.

. Lewis-j-d, . Enfield-k-b, . Cox-h-l, and . Mathers-a-j, Sifri C d. A single-center experience with infections due to daptomycin-nonsusceptible Enterococcus faecium in liver transplant recipients, Transpl Infect Dis, vol.18, issue.3, pp.341-53, 2016.

A. Dhand and G. Sakoulas, Reduced vancomycin susceptibility among clinical Staphylococcus aureus isolates ('the MIC Creep'): implications for therapy, F1000 Med Rep *Internet+, vol.4, 2012.

A. Soriano, F. Marco, J. A. Martinez, E. Pisos, M. Almela et al., Influence of Vancomycin Minimum Inhibitory Concentration on the Treatment of MethicillinResistant Staphylococcus aureus Bacteremia, Clin Infect Dis, vol.46, issue.2, pp.193-200, 2008.

M. Hentzien, C. Strady, V. Vernet-garnier, A. Servettaz, D. Champs et al., Prognostic factors associated with 30-day in-hospital mortality in coagulase-negative Staphylococcus bacteraemia: no impact of vancomycin minimum inhibitory concentration, vol.49, pp.664-73, 2017.

N. Sandoval, S. Grau, L. Sorlí, M. Montero, E. Esteve et al., Clinical experience with the use of daptomycin in a tertiary care teaching hospital in, Future Microbiol, vol.10, issue.7, pp.1145-54, 2015.

A. Dhand, A. S. Bayer, J. Pogliano, S. Yang, M. Bolaris et al., Use of Antistaphylococcal ?-Lactams to Increase Daptomycin Activity in Eradicating Persistent Bacteremia Due to Methicillin-Resistant Staphylococcus aureus: Role of Enhanced Daptomycin Binding, Clin Infect Dis, vol.53, issue.2, pp.158-63, 2011.

S. Mehta, C. Singh, K. B. Plata, P. K. Chanda, A. Paul et al., ?-lactams increase the antibacterial activity of daptomycin against clinical MRSA strains and prevent selection of DAP-resistant derivatives, Antimicrob Agents Chemother, pp.1525-1537, 2012.

G. Wu, T. Abraham, J. Rapp, F. Vastey, N. Saad et al., Daptomycin: evaluation of a highdose treatment strategy, Int J Antimicrob Agents, vol.38, issue.3, pp.192-198, 2011.

A. M. Casapao, R. Kullar, S. L. Davis, D. P. Levine, J. J. Zhao et al., Multicenter Study of High-Dose Daptomycin for Treatment of Enterococcal Infections, Antimicrob Agents Chemother, vol.57, issue.9, pp.4190-4196, 2013.

R. A. Seaton, F. Menichetti, G. Dalekos, A. Beiras-fernandez, F. Nacinovich et al., Evaluation of Effectiveness and Safety of High-Dose Daptomycin: Results from Patients Included in the European Cubicin® Outcomes Registry and Experience, Adv Ther, vol.32, issue.12, pp.1192-205, 2015.